X4 Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XFOR Nasdaq 8731 https://www.x4pharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for X4 Pharmaceuticals Inc

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1st, 2024 8:05 pm
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 - Apr 30th, 2024 12:00 pm
XFOR: XOLREMDI™ Approved by FDA… - Apr 30th, 2024 10:20 am
UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease - Apr 29th, 2024 10:47 am
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome - Apr 29th, 2024 10:30 am
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns - Apr 11th, 2024 2:15 pm
XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome… - Apr 2nd, 2024 10:16 am
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences - Apr 1st, 2024 12:00 pm
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript - Mar 22nd, 2024 4:47 pm
Q4 2023 X4 Pharmaceuticals Inc Earnings Call - Mar 22nd, 2024 2:09 am
X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results - Mar 21st, 2024 1:11 pm
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update - Mar 21st, 2024 10:01 am
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024 - Mar 12th, 2024 12:00 pm
XFOR: Update on Phase 2 CN Trial at ASH 2023 - Dec 15th, 2023 11:00 am
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023 - Dec 9th, 2023 5:00 pm
XFOR: Mavorixafor NDA Accepted by FDA; PDUFA Date of April 30, 2024 - Nov 13th, 2023 11:00 am
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call Transcript - Nov 10th, 2023 8:46 pm
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences - Nov 10th, 2023 1:00 pm
Q3 2023 X4 Pharmaceuticals Inc Earnings Call - Nov 10th, 2023 6:48 am
X4 Pharmaceuticals Inc (XFOR) Reports Q3 2023 Financial Results and Corporate Progress - Nov 9th, 2023 2:29 pm